RPTX - Repare Therapeutics GAAP EPS of $1.71 beats by $2.12 revenue of $112.5M beats by $83.22M
- Repare Therapeutics press release ( NASDAQ: RPTX ): Q3 GAAP EPS of $1.71 beats by $2.12 .
- Revenue of $112.5M beats by $83.22M .
- Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of September 30, 2022 were $370.4 million, which Repare believes will be sufficient to fund planned operations into 2026.
For further details see:
Repare Therapeutics GAAP EPS of $1.71 beats by $2.12, revenue of $112.5M beats by $83.22M